Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States
The safety and tolerability profile of X/T, coupled with its minimal PMPM budget impact of $0.0177 in year 1 up to $0.1006 in year 3, based on market uptake of 1%, 2%, and 3% in years 1, 2, and 3, respectively, supports the inclusion of X/T on the formularies of third-party US health care plans for adults with schizophrenia.
Authors
- Matthew Sidovar
- Aja Bjerke
- Tyler Mantaian
- Andrew Tunnicliffe
- J S Lee
- Kristin Gillard
- Jonathan Kowalski
Institutions
- Morristown Medical Center (US)
- Bristol-Myers Squibb (United States) (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2026-03-04
- DOI
- https://doi.org/10.18553/jmcp.2026.25256
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00